MedTrace Logo

Patient Portal Flu Vaccine Reminders (RCT 6)

NCT06062264 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22233

Last updated 2025-04-20

Study results available
· View outcomes & findings →

Summary

This trial is taking place in Los Angeles, CA at 21 clinics within the UCLA Health System.

The study design is a 3 arm randomized trial. Patients will be randomized into 1) receiving portal based reminder messages with a video from their PCP encouraging them to receive the influenza vaccine, 2) portal-based reminder messages with an infographic with the image of their PCP encouraging them to receive the influenza vaccine, or 3) the control group. Patients randomized to the intervention arms will receive reminders if they are due for influenza vaccine.

Despite the Advisory Committee on Immunization Practices (ACIP) recommendation in 2010 that all people above 6 months of age should receive an annual flu vaccine, vaccination rates remain low: at 6m-4.9 yrs. (70%), 5-17.9 yrs. (56%), 18-64.9 yrs. (38%), and \>65 yrs. (63%). The investigators will assess the effectiveness of MyChart R/R video messages and infographic messages as compared to the standard of care control (Health system messages).

Conditions

Interventions

BEHAVIORAL

Portal-based Video Message

Video recorded by physician encouraging patients to receive influenza vaccine. Sent via the patient portal.

BEHAVIORAL

Portal-based Infographic Message

Infographic with information about the influenza vaccine and an image of the physician. Sent via the patient portal.

Sponsors & Collaborators

Principal Investigators

  • Peter Szilagyi, MD, MPH · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-03
Primary Completion
2024-04-01
Completion
2024-04-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06062264 on ClinicalTrials.gov